Skip to content

BIOCRYST PHARMACEUTICALS INC

BCRX

CIK 0000882796

← back to feed
Revenue (TTM)
$29.06M
−4.4% YoY Q1 Apr 2026
Net Income (TTM)
−$703.8M
+396.9% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.90
+381.4% YoY Q1 Apr 2026
Gross Margin
48.6%
Q1 Apr 2026
Operating Margin
-2,137.0%
Q1 Apr 2026
Net Margin
-2,422.0%
Q1 Apr 2026
Free Cash Flow (TTM)
−$190.85M
Q1 Apr 2026
Cash
$171.59M
Q1 Apr 2026
Total Debt
$395.2M
Q1 Apr 2026
Shares Outstanding
254.16M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings